Dose escalation of a curcuminoid formulation
نویسندگان
چکیده
منابع مشابه
Dose escalation of a curcuminoid formulation
BACKGROUND Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed. METHODS A dose escalation study was conducted to determine the maximum tolerated dose and safety ...
متن کاملDose escalation pharmacokinetics of intranasal scopolamine gel formulation.
Astronauts experience Space Motion Sickness requiring treatment with an anti-motion sickness medication, scopolamine during space missions. Bioavailability after oral administration of scopolamine is low and variable, and absorption form transdermal patch is slow and prolonged. Intranasal administration achieves faster absorption and higher bioavailability of drugs that are subject to extrahepa...
متن کاملIndividualized Tamoxifen Dose Escalation-Letter.
In a recent commentary (1), Hertz and Rae have put the relevance of pharmacokinetically guided dosing of tamoxifen into perspective. We appreciate this effort and fully agree that more evidence is required to refine the relationship between exposure to the active tamoxifen metabolite endoxifen and clinical outcome parameters. On the basis of the relatively long survival of adjuvantly treated br...
متن کاملSystematic and comprehensive investigation of the toxicity of curcuminoid‑essential oil complex: A bioavailable turmeric formulation.
Curcumin, the active component present in Curcuma longa of the family Zingiberaceae, has a number of pharmacological effects, including potential anti‑inflammatory activity. One of the major limitations of curcumin/turmeric extract is its poor absorption through the gastrointestinal tract. Several approaches have been adopted to increase the bioavailability of curcumin, including loading curcum...
متن کاملAdalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
BACKGROUND AND AIMS Adalimumab is efficacious in inducing and maintaining remission in Crohn's disease but dose escalation is needed in 30-40% after 1 year. Attempts for dose de-escalation have not been studied. This study aimed to assess the need for, predictors, and outcome of dose escalation and de-escalation in a large cohort of adalimumab treated Crohn's patients. METHODS All consecutive...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Complementary and Alternative Medicine
سال: 2006
ISSN: 1472-6882
DOI: 10.1186/1472-6882-6-10